Drug Therapy in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis
Authors:
- 1 February 1990
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 18 (2) , 104-117
Abstract
Continuous ambulatory peritoneal dialysis (CAPD) is an accepted alternative to haemodialysis in the treatment of end-stage renal failure. The frequently used intraperitoneal administration of antibiotics to treat peritonitis and the possible role of CAPD in the elimination of drugs has stimulated pharmacokinetic research in this field. The 2 principal results derived from these studies are: (1) the elimination capacity of CAPD for drugs given systemically or orally is very low, and (2) drugs administered intraperitoneally rapidly enter the circulation, a significant amount of drug being absorbed from the peritoneal cavity. This pharmacokinetic behaviour is easily understood considering some basic and simple pharmacokinetic principles: the higher the volume of distribution of a substance, the lower will be the percentage of drug present in the peritoneal cavity. Thus, a prerequisite for rapid drug elimination by CAPD is a low body volume of distribution of a particular drug. Only in such a case will the drug diffuse into the peritoneal space to a significant extent. For dosing regimens in CAPD patients, the fraction of the dose eliminated by the peritoneal route should be known or estimated. This fraction depends on the relation of the peritoneal clearance to the total body clearance, and on the protein binding of the drug. The low flow rate of the peritoneal effluent (approximately 10 L/day = 7 ml/min) appears to be the most important limiting factor for the low extraction capacity of CAPD. The list of drugs that have been found to be significantly eliminated by CAPD is short: particular mention should be made of the aminoglycosides and some cephalosporins. The data on the peritoneal elimination of vancomycin are inconsistent. Although the intravenous and oral routes have been successfully used for the treatment of peritonitis, the time course of antibiotic concentrations in the peritoneal space appears to favour the peritoneal route of drug administration. During peritonitis, intraperitoneally administered drugs enter the circulation more rapidly and completely, due to the increased permeability of the peritoneal membrane. As long as the dialysate outflow rate and protein binding of the drug are not extensively altered by peritoneal inflammation, however, the extraction capacity of CAPD appears to remain low.Keywords
This publication has 78 references indexed in Scilit:
- Comparative Study of the Pharmacokinetics of Various β-Lactams after Intravenous and Intraperitoneal Administration in Patients Undergoing Continuous Ambulatory Peritoneal DialysisDrugs, 1988
- Phamacokinetics of a single intravenous dose of teicoplanin in subjects with various degrees of renal impairmentJournal of Antimicrobial Chemotherapy, 1988
- Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysisAntimicrobial Agents and Chemotherapy, 1988
- Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysisEuropean Journal of Clinical Pharmacology, 1987
- Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysisJournal of Antimicrobial Chemotherapy, 1987
- Angiotensin I in peritoneal dialysis fluid improved hypotension: a case report.1987
- KETOCONAZOLE AND FUNGAL CAPD PERITONITISThe Lancet, 1983
- Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysisClinical Pharmacology & Therapeutics, 1982
- Stability of antimicrobial agents in peritoneal dialysateAntimicrobial Agents and Chemotherapy, 1982
- Protein losses during peritoneal dialysisKidney International, 1981